Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
Frenette C, Kayali Z, Mena E, Mantry PS, Lucas KJ, Neff G, Rodriguez M, Thuluvath PJ, Weinberg E, Bhandari BR, Robinson J, Wedick N, Chan JL, Hagerty DT, Kowdley KV; IDN-6556-17 Study Investigators.
Frenette C, et al.
J Hepatol. 2021 Feb;74(2):274-282. doi: 10.1016/j.jhep.2020.09.029. Epub 2020 Oct 8.
J Hepatol. 2021.
PMID: 33038432
Clinical Trial.